• Selective CUX2 Neuron Loss Linked to DNA Damage in Neuroinfl

  2026-07-27

  This study uncovers a mechanism by which DNA damage specifically burdens and depletes CUX2-expressing layer 2/3 cortical neurons during neuroinflammation, such as in multiple sclerosis. The work establishes DNA repair capacity as a key determinant of selective neuronal vulnerability and opens new research avenues for neurodegenerative disease modeling.

• Omeprazole (A2845): Protocols for Gastric Acid Research

  2026-07-26

  Omeprazole (SKU A2845) is a high-purity H+,K+-ATPase inhibitor for laboratory-based studies of gastric acid secretion and antiulcer mechanisms. It is not suitable for clinical, diagnostic, or therapeutic use, and should be handled according to strict research protocols to ensure reproducibility and compound stability.

• Phosbind Biotin LC: Sequence-Independent Phosphorylation Det

  2026-07-25

  Phosbind Biotin LC provides a robust, antibody-free approach for detecting phosphorylated proteins on PVDF membranes in Western Blot workflows. It is best suited for experiments where phospho-specific antibodies are unavailable or limited by sequence context. This reagent should not be used in aqueous-only protocols or where long-term storage of working solutions is required.

• Calpeptin: Nanomolar Calpain Inhibitor for Fibrosis Research

  2026-07-24

  Calpeptin enables precise inhibition of calpain pathways, empowering researchers to dissect fibrosis and inflammation mechanisms with nanomolar sensitivity. Its robust solubility and validated in vitro and in vivo efficacy make it the gold-standard tool for advanced pulmonary fibrosis and cell death studies.

• Dual-Action Kinase Inhibitors Accelerate p38α MAPK Dephospho

  2026-07-24

  This study uncovers that certain kinase inhibitors not only block p38α MAPK activity but also promote its dephosphorylation by phosphatases. The findings advance our understanding of how conformational modulation can improve specificity and potency in inflammatory signaling research.

• Salvianolic Acid B: Transforming Antifibrotic Research via L

  2026-07-23

  Explore how Salvianolic acid B (Dan Shen Suan B) is reframing the antifibrotic landscape by directly targeting LH2-mediated collagen cross-linking. This article synthesizes emerging mechanistic insights, protocol guidance, and strategic outlook for translational researchers seeking to accelerate innovation in pulmonary fibrosis and extracellular matrix remodeling.

• HOBt: Driving Strategic Innovation in Translational Peptide

  2026-07-23

  Explore how HOBt (1-Hydroxybenzotriazole) is redefining peptide synthesis at the mechanistic and strategic levels, with actionable insights for translational research teams. This article bridges cutting-edge chemistry with practical guidance, illuminating HOBt’s pivotal role in enabling next-generation therapeutics, including complex amide analogues and glucagon receptor antagonists. Backed by recent literature and APExBIO’s product expertise, the discussion targets real-world challenges, competitive trends, and the future of high-fidelity peptide engineering.

• Metoprolol Tartrate in Hematopoietic and Cardiovascular Mode

  2026-07-22

  Explore Metoprolol Tartrate as a β1-adrenergic blocking agent for advanced cardiovascular and hematopoietic research. This article uncovers its selective mechanism, unique implications for engraftment models, and practical assay strategies distinct from prior content.

• Standardizing 3D Tumor Spheroid Assays for Glioblastoma Stem

  2026-07-22

  This study introduces a streamlined, reproducible 3D-tumor spheroid assay for detecting stemness in glioblastoma cell lines. By enabling rapid, high-throughput evaluation of glioma stem-like phenotypes, this method accelerates both basic research and drug screening focused on tumor-initiating cells.

• PRDX6-GPX4 Axis: Enhancing Ferroptosis for Tumor Suppression

  2026-07-21

  Hu et al. (2025) reveal how PRDX6 modulates GPX4 localization and function, providing dual protection against lipid peroxidation and conferring ferroptosis resistance in tumors. The study establishes that inhibiting PRDX6 disrupts this defense, intensifies ferroptosis, and suppresses tumor progression, offering new strategies for targeted cancer therapy.

• Norepinephrine:Angiotensin II Ratio in Vasodilatory Hypotens

  2026-07-21

  This article reviews a post-hoc analysis of the ARAMIS trial, which establishes a definitive norepinephrine to angiotensin II conversion ratio for patients with vasodilatory hypotension. The findings clarify a key dosing metric for critical care research and protocol development, with implications for standardizing vasopressor comparisons and optimizing treatment strategies.

• Naloxone Hydrochloride: Optimizing Opioid Receptor Antagonis

  2026-07-20

  Naloxone hydrochloride’s versatility as an opioid receptor antagonist extends beyond overdose modeling, powering advanced research in neural stem cell proliferation and behavioral neuroscience. This article delivers actionable workflows, troubleshooting guidance, and stepwise protocols anchored in peer-reviewed evidence and the high-purity standard set by APExBIO.

• Grazoprevir hydrate (SKU C8713): Optimizing HCV Assay Outcom

  2026-07-20

  This article provides a scenario-driven, evidence-based guide to leveraging Grazoprevir hydrate (SKU C8713) in hepatitis C virus (HCV) research workflows. Covering experimental design, protocol optimization, data interpretation, and product reliability, it demonstrates how APExBIO’s Grazoprevir hydrate enables reproducible, sensitive, and clinically relevant results for cell viability and viral inhibition assays.

• 5-HT3 Antagonists Inhibit Renal OCT2 and MATE1 Transporters

  2026-07-19

  This study systematically evaluates the ability of five 5-HT3 receptor antagonists, including Tropisetron Hydrochloride, to inhibit the renal transporters OCT2 and MATE1 in vitro. The findings highlight the potential for drug-drug interactions at the level of renal secretion, with practical implications for serotonin receptor signaling research and pharmacokinetic modeling.

• P2Y11 Antagonist NF 340: Precision Tools for Inflammation Pa

  2026-07-18

  NF 340 empowers researchers to dissect purinergic receptor signaling with unparalleled specificity, enabling advanced study of immune and cancer pathways. This guide details robust experimental workflows, troubleshooting strategies, and translational insights from recent breakthroughs using this potent P2Y11 antagonist.

451 records 10/31 page Previous Next First page 上5页 678910 下5页 Last page